GET DAILY SIGNALSNeuronetics (STIM) Drops -26% in 30 Days as Financing Moves Overshadow Q3 Results
Key Takeaways
- Neuronetics (STIM) shares declined roughly 26% over the trailing 30 days, falling from about $1.99 to near $1.47.
- The move was driven mainly by a dilutive $30 million equity offering and credit-agreement concerns, which outweighed a better-than-expected third-quarter earnings report.
- Q3 2026 revenue rose 12.5% year over year to $42.0 million, and the company swung to positive operating income, yet the stock reversed after an initial post-earnings pop.
- The company's latest Form 10-Q referenced going-concern risk, which management expects to resolve through a credit-facility amendment contingent on a $15 million prepayment.
- Over the trailing quarter, the stock has declined more than 50%, reflecting ongoing cash utilization and share dilution.
- For additional detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- See how top-performing automated strategies approach stocks like STIM by visiting Trending AI Robots.
Neuronetics (STIM) Business Overview
Neuronetics, Inc. operates as a commercial-stage medical technology firm focused on interventional mental health. Its NeuroStar Advanced Therapy System delivers transcranial magnetic stimulation (TMS), a non-drug, noninvasive treatment cleared by the FDA for major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and anxious depression. Through the Greenbrook TMS subsidiary, the company runs one of the largest interventional psychiatry clinic networks in the United States, providing both TMS and SPRAVATO (esketamine) nasal spray therapies.
The business mixes capital equipment sales and placements with recurring treatment-session revenue, plus direct patient care at the clinics. I follow STIM for its exposure to the expanding behavioral and interventional mental health market, along with management’s push toward sustained profitability.
STIM Stock Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, STIM fell approximately 26%, moving from a closing price near $1.99 down to around $1.47. The path was uneven, with shares rallying into late October before a sharp selloff in early November that aligned with the quarterly report and financing announcements.
The three-month picture looks steeper still. From roughly $3.20 in mid-August, the stock has dropped more than 50%. This gap between improving operations and the share-price slide highlights how financing and balance-sheet issues have weighed on sentiment recently. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Drivers Behind the Recent 30-Day Decline
The main catalyst was capital-markets activity. On November 10, Neuronetics announced a $30 million underwritten public offering of common stock sold by the company, which diluted shareholders and weighed on the price. Part of the proceeds were intended to repay a portion of the outstanding term loan.
Balance-sheet worries added pressure. The latest Form 10-Q flagged going-concern risk, and on November 5 the company entered a sixth amendment to its credit agreement with Perceptive Credit Holdings. The amendment eases certain revenue covenants but requires a prepayment of at least $15 million by November 30; management believes meeting those conditions will resolve the going-concern designation.
These factors overshadowed a solid third quarter. Reported on November 4, Q3 2026 revenue reached $42.0 million, up 12.5% year over year. Gross margin expanded to 52.2% from 45.9%, and the company posted operating income of $0.5 million versus a $7.3 million loss a year earlier. Adjusted EBITDA turned positive at $1.9 million. Shares rose initially on the results before reversing on the financing news.
Performance Drivers Over the Trailing Quarter
Across the past three months, investor focus has remained on liquidity and dilution rather than operational progress. Neuronetics has used its at-the-market facility to raise capital, issuing millions of shares and increasing the share count, while cash fell to $27.9 million as of September 30, 2026, from $34.1 million at year-end 2025.
Operationally, Greenbrook revenue grew 20.1% year over year in the third quarter, helped by revenue-cycle improvements and growth in esketamine therapy. NeuroStar system sales hit a record quarter, although session revenue continued to decline as the company shifted toward capital and lease placements. Those positive trends have not yet offset the overhang from financing needs and covenant uncertainty.
What to Watch for STIM Stock Going Forward
Several items will matter in the coming months. First is the outcome of the $30 million offering and whether the credit-agreement amendment conditions are met, as that will affect the going-concern status and near-term liquidity. Second is full-year 2026 guidance, which calls for revenue between $160 million and $164 million and gross margin between 49% and 50%.
Other potential catalysts include the pending FDA 510(k) review for an accelerated TMS protocol, the new distribution agreement with Wave Neuroscience for PTSD-focused treatment, and integration of the TrakStar platform with AdvancedMD’s electronic health record system. Demand trends in NeuroStar placements and Greenbrook clinic occupancy, plus any further capital raises, will stay central to how the market values the shares. I’m watching this closely through both traditional filings and data tools.
AI Tools Supporting My Analysis
I’ve found Tickeron’s AI Trading Bots useful when reviewing automated strategies that have performed well on names like STIM. The platform lets me compare different approaches and holding periods side by side, which adds a data-driven angle to traditional research without replacing fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STIM in +31.31% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STIM advanced for three days, in 227 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STIM's RSI Oscillator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STIM as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for STIM turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STIM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for STIM entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.178) is normal, around the industry mean (4.142). P/E Ratio (-5.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive therapies for psychiatric and neurological disorders
Industry MedicalNursingServices
Advertisement